Clinical trials for Haemophilus influenzae type b

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Haemophilus influenzae type b. For all clinical trials, go to clinical trials search

This list shows clinical trials for Haemophilus influenzae type b

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Haemophilus influenzae type b
Title Recruitment status Location
A phase IV study to evaluate the primary and booster immune responses of UK infants receiving a licensed 6-in-1 DTaP/IPV/Hib/HBV vaccine (Infanrix-Hexa) with a 13valent pneumococcal conjugate vaccine and incorporating a randomisation study of a single dose of 3 different meningococcal group C conjugate vaccines at 3 months of age Recruiting United Kingdom
Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine Not recruiting United Kingdom
A phase III randomised, open label clinical trial evaluating the immunogenicity of a 10-valent pneumococcal conjugate vaccine booster compared to the standard 13-valent pneumococcal conjugate vaccine booster given at 12 months of age to healthy children who have received the 13-valent pneumococcal conjugate vaccine at 2 and 4 months of age Not Recruiting United Kingdom
A phase II, open-label, randomised study to assess the safety and immunogenicity of a birth dose of GSK Biologicals’ reduced-antigen-content tri-component pertussis vaccine followed by routine paediatric vaccination at 2, 4, 6 and 12-18 months of age, and to explore the ability of this schedule to accelerate the acquisition of pertussis antibodies. - PA-TRICOMP-005 Not Recruiting United Kingdom
Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study Not recruiting United Kingdom
A phase II, open-label, randomized, multicentre study to evaluate the feasibility of GSK Biologicals’ DTPa-IPV/Hib-MenC-TT vaccine co-administered with Prevenar compared with Pediacel co-administered with Menjugate and Prevenar, when given in healthy infants as a three-dose primary vaccination course at 2, 3 and 4 months of age and to evaluate Menitorix given to these children as a booster dose at 12 months of age - DTPA-IPV=HIB-MENC-TT-001 PRI Not Recruiting United Kingdom
Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants Not recruiting United Kingdom
Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine Not recruiting United Kingdom
Multiboost - MCC plus pertussis booster in adolescents Not Recruiting United Kingdom
Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules Not recruiting United Kingdom

Page last reviewed:

Next review due: